Barclays analyst Peter Lawson lowered the firm’s price target on Prelude Therapeutics to $3 from $5 and keeps an Equal Weight rating on the shares post the Q3 report. The analyst updated the company’s model to reflect the company’s pipeline prioritization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRLD:
- Prelude Therapeutics updates pipeline ‘s clinical progress, prioritization
- Prelude, AbCellera team on precision antibody drug conjugates in oncology
- Prelude Therapeutics reports Q3 EPS (45c), consensus (58c)
- Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results
- Prelude Therapeutics price target lowered to $6 from $17 at H.C. Wainwright
